Five things: A Flagship failure, more cannabis intrigue, books to read and Harvard for Santas

Good morning, everyone. Here are the five things you need to know in Boston business news to start your Wednesday.

A Flagship Pioneering-backed biotech behind one of the only new drugs in development for long Covid is closing its doors, Rowan Walrath reports.

Rowan also reports that serial entrepreneur Gary Glick's latest startup has $101 million in fresh funds as it marches toward human trials, starting with gastrointestinal disease.

A highly-anticipated hearing between Cannabis Control…

Previous Fearless wins $35M contract to build 'front door' to the CDC
Next Inside the deal: How a DC developer is making affordable housing work in St. Pete